Claims

1. Formulation containing a soluble Fcγ receptor (sFcγR) in an aqueous buffered solution, wherein the concentration of the soluble Fcγ receptor is greater than 60 mg/ml and wherein it contains a physiologically acceptable buffer substance.

2. Formulation according to claim 1, wherein the buffer substance is selected from histidine, citrate, phosphate or any combination thereof.

3. Formulation according to claim 1 or 2, wherein the receptor is a FcγRII receptor, preferably FcγRIIB.

4. Formulation according to anyone of the previous claims, wherein the concentration of the Fcγ receptor is greater than 80 mg/ml, preferably greater than 100mg/ml, more preferably greater than 150 mg/ml and most preferably greater than 200 mg/ml.

5. Formulation according to anyone of the previous claims, wherein it contains further substances selected from sugars, salts and detergents.

6. Formulation according to anyone of the previous claims, wherein the receptor is present in dissolved form or the formulation contains the receptor in a microcrystalline form.

7. Formulation according to claims 5 or 6, wherein it is a citrate buffered solution and the pH of the formulation is adjusted to from 6.0 to 7.5.

8. Formulation according to claims 5 or 6, wherein it is a histidine buffered solution and the pH is adjusted to from 5.2 to 5.9.

9. Formulation according to anyone of claims 1 to 5, wherein it contains the receptor in a crystalline form.

10. Formulation according to anyone of claims 6 and 9, wherein it is a citrate buffered solution and its pH is adjusted to from 5.2 to 5.9.

11. Formulation according to anyone of claims 6 and 9, wherein it is a histidine buffered solution and its pH is adjusted to from 6.0 to 7.5.

12. Pharmaceutical composition comprising a formulation according to anyone of claims 1 to 11, optionally in combination with pharmaceutically acceptable excipients and/or adjuvants and/or carriers.

13. Pharmaceutical composition according to claim 12 for the subcutaneous injection of an effective amount of an Fcγ receptor for use in the prevention or treatment of autoimmune diseases or inflammatory diseases.

14. Formulation according to anyone of claims 1 to 11 or a pharmaceutical composition according to claims 12 or 13 for use in the treatment or prevention of autoimmune diseases, in particular of multiple sclerosis, systemic lupus erythematosus, rheumatoid arthritis, primary immune thrombocytopenia or autoimmune hematolytic anemia.